Kronos Bio Inc reports results for the quarter ended September 30 - Earnings Summary

Kronos Bio

14/11/2024 04:02

* Kronos Bio Inc  KRON.OQ  reported a quarterly adjusted
loss
of 23 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -54 cents.  The mean expectation of
four analysts for the quarter was for a loss of 28 cents per
share. Wall Street expected results to range from -32 cents
to -20 cents per share.
    * Revenue rose 158.5% to $2.37 million from a year ago;
analysts
expected $2.10 million. 
    * Kronos Bio Inc's reported EPS for the quarter was a loss
of 23
cents​.
    * The company reported a quarterly loss of $14.11 million.
    * Kronos Bio Inc shares had fallen by 8.0% this quarter and
lost 26.4% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Kronos Bio Inc is
1.63 
This summary was machine generated from LSEG data November 14 at
04:01 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.28          -0.23          Beat
 Jun. 30 2024      -0.34                         
 Mar. 31 2024                                    
 Dec. 31 2023      -0.52          -0.34          Beat